NTRK1 and neoplasm: It has been reported that sorafenib suppresses tumor angiogenesis and proliferation by inhibiting the signals mediated by serine/threonine kinases, such as Raf/MEK/ERK1/2 cascade, as well as the signals mediated by receptor tyrosine kinases, such as FGFR, VEGFR, and PDGFR.